Cite
APA Citation
Morishima, C., McNeel, D. G., Patel, M. R., Kohrt, H., Waldmann, T. A., Thompson, J. A., Conlon, K., M Sondel, P., Wakelee, H., Disis, M. L., Creekmore, S. P., & Miller, J. S. (n.d.). cITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells. Journal for immunotherapy of cancer, 2, . http://access.bl.uk/ark:/81055/vdc_100135555081.0x000004